SUBSCRIBE
SUBSCRIBE

Horizon Therapeutics

NEWS
Horizon Therapeutics was acquired by Amgen in 2023.
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Horizon Pharma Craters as Rare Neuromuscular Drug Flunks Late-Stage Study
December 8, 2016
 · 
2 min read
San Diego's Halozyme Lands Monster R&D Deals Worth $2 Billion+ From Bristol-Myers Squibb and Roche
Deals
Another One Bites the Dust... Horizon Pharma Takes Out Bay Area’s Raptor in $800 Million Deal
September 12, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
3 Battered Biopharma Stocks Battling to Recover
July 22, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
Orphan Drug Company Horizon Pharma Projects $1 Billion+ Sales for 2016, to Double Jobs by 2020
February 9, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Horizon Pharma Lashes Out at Express Scripts After Benefits Manager Severs Ties
November 12, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Horizon Pharma Fires Back at the New York Times Report on Prescriptions Made Easy Practice
October 22, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
Amidst Hostile Takeover Attempt of Depomed, Horizon Pharma Triples Size of U.S. Headquarters
October 5, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Horizon Pharma Files Lawsuit, Seeks Change of Depomed’s Board of Directors in Takeover Attempt
August 4, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Horizon Pharma Goes Hostile With $3 Billion Bid for Depomed
July 7, 2015
 · 
2 min read
Load More

AWARDS
  • 2022 Best Places to Work
IN THE PRESS
BioMidwest
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
October 22, 2022
 · 
6 min read
Job Trends
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
October 13, 2022
 · 
5 min read
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
October 12, 2022
 · 
7 min read
Business
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
October 6, 2022
 · 
1 min read
BioMidwest
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
October 2, 2022
 · 
5 min read
Drug Development
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
September 29, 2022
 · 
7 min read
Business
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
September 22, 2022
 · 
3 min read
Business
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
September 21, 2022
 · 
4 min read
Business
HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline
September 21, 2022
 · 
3 min read
Job Trends
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
September 19, 2022
 · 
6 min read
Load More